NO324775B1 - Renset peptid, isolert nukleinsyresekvens og deres anvendelse. - Google Patents

Renset peptid, isolert nukleinsyresekvens og deres anvendelse. Download PDF

Info

Publication number: NO324775B1
Authority: NO; Norway
Prior art keywords: polypeptide; stated; nucleic acid; sequence seq; acid sequence
Prior art date: 1995-12-06

Application number

NO19982550A

Other languages

English (en)

Norwegian (no)

Other versions

NO982550D0 (no

NO982550L (no

Inventor

Daniel Caput

Pascual Ferrara

Patrick Laurent

Natalio Vita

Original Assignee

Sanofi Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-06

Filing date

1998-06-04

Publication date

2007-12-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9485198&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO324775(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-06-04 Application filed by Sanofi Aventis filed Critical Sanofi Aventis

1998-06-04 Publication of NO982550D0 publication Critical patent/NO982550D0/no

1998-08-05 Publication of NO982550L publication Critical patent/NO982550L/no

2007-12-10 Publication of NO324775B1 publication Critical patent/NO324775B1/no

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims description 89
108091028043 Nucleic acid sequence Proteins 0.000 title claims description 32
150000007523 nucleic acids Chemical group 0.000 title claims description 32
102000003816 Interleukin-13 Human genes 0.000 claims description 120
108090000176 Interleukin-13 Proteins 0.000 claims description 120
210000004027 cell Anatomy 0.000 claims description 113
102000004196 processed proteins & peptides Human genes 0.000 claims description 88
229920001184 polypeptide Polymers 0.000 claims description 87
108010017511 Interleukin-13 Receptors Proteins 0.000 claims description 74
102000004559 Interleukin-13 Receptors Human genes 0.000 claims description 73
239000002773 nucleotide Substances 0.000 claims description 37
125000003729 nucleotide group Chemical class 0.000 claims description 37
239000012634 fragment Substances 0.000 claims description 23
230000014509 gene expression Effects 0.000 claims description 19
239000000523 sample Substances 0.000 claims description 19
230000000694 effects Effects 0.000 claims description 18
238000004519 manufacturing process Methods 0.000 claims description 17
108020004999 messenger RNA Proteins 0.000 claims description 16
150000001413 amino acids Chemical class 0.000 claims description 12
239000013598 vector Substances 0.000 claims description 12
125000003275 alpha amino acid group Chemical group 0.000 claims description 11
238000010367 cloning Methods 0.000 claims description 11
230000000295 complement effect Effects 0.000 claims description 10
239000013612 plasmid Substances 0.000 claims description 10
230000004071 biological effect Effects 0.000 claims description 9
239000000825 pharmaceutical preparation Substances 0.000 claims description 8
230000000692 anti-sense effect Effects 0.000 claims description 6
239000013604 expression vector Substances 0.000 claims description 6
230000002068 genetic effect Effects 0.000 claims description 6
239000003795 chemical substances by application Substances 0.000 claims description 5
239000013599 cloning vector Substances 0.000 claims description 5
230000003042 antagnostic effect Effects 0.000 claims description 4
230000035772 mutation Effects 0.000 claims description 4
238000012216 screening Methods 0.000 claims description 4
238000007792 addition Methods 0.000 claims description 3
238000007385 chemical modification Methods 0.000 claims description 3
238000012217 deletion Methods 0.000 claims description 3
230000037430 deletion Effects 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
230000037456 inflammatory mechanism Effects 0.000 claims description 3
238000006467 substitution reaction Methods 0.000 claims description 3
125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 2
229940079593 drug Drugs 0.000 claims description 2
230000007233 immunological mechanism Effects 0.000 claims description 2
238000013518 transcription Methods 0.000 claims description 2
230000035897 transcription Effects 0.000 claims description 2
102000012740 beta Adrenergic Receptors Human genes 0.000 claims 1
108010079452 beta Adrenergic Receptors Proteins 0.000 claims 1
230000007850 degeneration Effects 0.000 claims 1
230000027455 binding Effects 0.000 description 60
102000005962 receptors Human genes 0.000 description 59
108020003175 receptors Proteins 0.000 description 59
239000002299 complementary DNA Substances 0.000 description 57
238000002474 experimental method Methods 0.000 description 22
108090000623 proteins and genes Proteins 0.000 description 21
239000000872 buffer Substances 0.000 description 20
210000004978 chinese hamster ovary cell Anatomy 0.000 description 19
238000000034 method Methods 0.000 description 18
235000018102 proteins Nutrition 0.000 description 17
102000004169 proteins and genes Human genes 0.000 description 17
108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
102000004127 Cytokines Human genes 0.000 description 13
108090000695 Cytokines Proteins 0.000 description 13
239000012528 membrane Substances 0.000 description 13
238000004458 analytical method Methods 0.000 description 12
239000000203 mixture Substances 0.000 description 12
235000001014 amino acid Nutrition 0.000 description 11
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
108010038486 Interleukin-4 Receptors Proteins 0.000 description 10
102000010787 Interleukin-4 Receptors Human genes 0.000 description 10
239000006228 supernatant Substances 0.000 description 10
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
238000004132 cross linking Methods 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 9
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 description 8
108040003607 interleukin-13 receptor activity proteins Proteins 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
108020004414 DNA Proteins 0.000 description 7
239000000284 extract Substances 0.000 description 7
239000002609 medium Substances 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
230000028327 secretion Effects 0.000 description 7
239000000243 solution Substances 0.000 description 7
108020004635 Complementary DNA Proteins 0.000 description 6
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
101001003135 Homo sapiens Interleukin-13 receptor subunit alpha-1 Proteins 0.000 description 6
102100020791 Interleukin-13 receptor subunit alpha-1 Human genes 0.000 description 6
102000004889 Interleukin-6 Human genes 0.000 description 6
108090001005 Interleukin-6 Proteins 0.000 description 6
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
238000012512 characterization method Methods 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
239000000047 product Substances 0.000 description 6
238000013391 scatchard analysis Methods 0.000 description 6
108010076504 Protein Sorting Signals Proteins 0.000 description 5
239000005557 antagonist Substances 0.000 description 5
210000000170 cell membrane Anatomy 0.000 description 5
238000009396 hybridization Methods 0.000 description 5
238000002372 labelling Methods 0.000 description 5
239000008188 pellet Substances 0.000 description 5
238000003752 polymerase chain reaction Methods 0.000 description 5
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
241001529936 Murinae Species 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
230000004913 activation Effects 0.000 description 4
230000033228 biological regulation Effects 0.000 description 4
238000010804 cDNA synthesis Methods 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
238000001514 detection method Methods 0.000 description 4
238000000605 extraction Methods 0.000 description 4
238000011534 incubation Methods 0.000 description 4
108040006859 interleukin-5 receptor activity proteins Proteins 0.000 description 4
238000002955 isolation Methods 0.000 description 4
230000037230 mobility Effects 0.000 description 4
238000000746 purification Methods 0.000 description 4
230000002285 radioactive effect Effects 0.000 description 4
239000002287 radioligand Substances 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
238000001890 transfection Methods 0.000 description 4
101100497384 Drosophila melanogaster CASK gene Proteins 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
102100034343 Integrase Human genes 0.000 description 3
102000018697 Membrane Proteins Human genes 0.000 description 3
108010052285 Membrane Proteins Proteins 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
230000004988 N-glycosylation Effects 0.000 description 3
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
206010038389 Renal cancer Diseases 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
230000003321 amplification Effects 0.000 description 3
210000003719 b-lymphocyte Anatomy 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
229910001629 magnesium chloride Inorganic materials 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
238000003199 nucleic acid amplification method Methods 0.000 description 3
230000007170 pathology Effects 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
201000010174 renal carcinoma Diseases 0.000 description 3
230000010076 replication Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
230000010474 transient expression Effects 0.000 description 3
238000013519 translation Methods 0.000 description 3
229920001817 Agar Polymers 0.000 description 2
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
239000005695 Ammonium acetate Substances 0.000 description 2
241000972773 Aulopiformes Species 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
108010067770 Endopeptidase K Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
108010038453 Interleukin-2 Receptors Proteins 0.000 description 2
102000010789 Interleukin-2 Receptors Human genes 0.000 description 2
238000000636 Northern blotting Methods 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
108020005187 Oligonucleotide Probes Proteins 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
102000001708 Protein Isoforms Human genes 0.000 description 2
108010029485 Protein Isoforms Proteins 0.000 description 2
208000006265 Renal cell carcinoma Diseases 0.000 description 2
102000013968 STAT6 Transcription Factor Human genes 0.000 description 2
108010011005 STAT6 Transcription Factor Proteins 0.000 description 2
239000007984 Tris EDTA buffer Substances 0.000 description 2
108090000631 Trypsin Proteins 0.000 description 2
102000004142 Trypsin Human genes 0.000 description 2
108091068141 Type II family Proteins 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
239000008272 agar Substances 0.000 description 2
229940043376 ammonium acetate Drugs 0.000 description 2
235000019257 ammonium acetate Nutrition 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000011324 bead Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
230000004186 co-expression Effects 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
102000003675 cytokine receptors Human genes 0.000 description 2
108010057085 cytokine receptors Proteins 0.000 description 2
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
OGGXGZAMXPVRFZ-UHFFFAOYSA-N dimethylarsinic acid Chemical compound C[As](C)(O)=O OGGXGZAMXPVRFZ-UHFFFAOYSA-N 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
229920001519 homopolymer Polymers 0.000 description 2
102000006426 human interleukin-13 receptor Human genes 0.000 description 2
108010044118 human interleukin-13 receptor Proteins 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
229940126601 medicinal product Drugs 0.000 description 2
102000006240 membrane receptors Human genes 0.000 description 2
108020004084 membrane receptors Proteins 0.000 description 2
238000000329 molecular dynamics simulation Methods 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
210000004967 non-hematopoietic stem cell Anatomy 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
239000002751 oligonucleotide probe Substances 0.000 description 2
230000002018 overexpression Effects 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
230000008488 polyadenylation Effects 0.000 description 2
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
230000000284 resting effect Effects 0.000 description 2
235000019515 salmon Nutrition 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000009466 transformation Effects 0.000 description 2
239000001226 triphosphate Substances 0.000 description 2
235000011178 triphosphate Nutrition 0.000 description 2
125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 2
239000012588 trypsin Substances 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
101100069857 Caenorhabditis elegans hil-4 gene Proteins 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
208000036566 Erythroleukaemia Diseases 0.000 description 1
241001288713 Escherichia coli MC1061 Species 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 description 1
108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
101001077604 Homo sapiens Insulin receptor substrate 1 Proteins 0.000 description 1
101000960936 Homo sapiens Interleukin-5 receptor subunit alpha Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102100025087 Insulin receptor substrate 1 Human genes 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
108010038452 Interleukin-3 Receptors Proteins 0.000 description 1
102000010790 Interleukin-3 Receptors Human genes 0.000 description 1
108010002616 Interleukin-5 Proteins 0.000 description 1
108010038484 Interleukin-5 Receptors Proteins 0.000 description 1
102000010786 Interleukin-5 Receptors Human genes 0.000 description 1
101150009057 JAK2 gene Proteins 0.000 description 1
239000006142 Luria-Bertani Agar Substances 0.000 description 1
239000007993 MOPS buffer Substances 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
OAICVXFJPJFONN-OUBTZVSYSA-N Phosphorus-32 Chemical compound [32P] OAICVXFJPJFONN-OUBTZVSYSA-N 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
108010002519 Prolactin Receptors Proteins 0.000 description 1
102100029000 Prolactin receptor Human genes 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108091034057 RNA (poly(A)) Proteins 0.000 description 1
239000013614 RNA sample Substances 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
239000012506 Sephacryl® Substances 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
239000008049 TAE buffer Substances 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
108091036066 Three prime untranslated region Proteins 0.000 description 1
102000000887 Transcription factor STAT Human genes 0.000 description 1
108050007918 Transcription factor STAT Proteins 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000012190 activator Substances 0.000 description 1
208000021841 acute erythroid leukemia Diseases 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
230000007815 allergy Effects 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
229950004243 cacodylic acid Drugs 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000012136 culture method Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000000539 dimer Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
238000009826 distribution Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000009510 drug design Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
210000001671 embryonic stem cell Anatomy 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000009144 enzymatic modification Effects 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
238000001215 fluorescent labelling Methods 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
-1 host cell Substances 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
229940127121 immunoconjugate Drugs 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
230000004957 immunoregulator effect Effects 0.000 description 1
229940051026 immunotoxin Drugs 0.000 description 1
239000002596 immunotoxin Substances 0.000 description 1
230000002637 immunotoxin Effects 0.000 description 1
231100000608 immunotoxin Toxicity 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
108010052754 interleukin-14 receptor Proteins 0.000 description 1
108040002039 interleukin-15 receptor activity proteins Proteins 0.000 description 1
102000008616 interleukin-15 receptor activity proteins Human genes 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 1
229940044173 iodine-125 Drugs 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
239000011654 magnesium acetate Substances 0.000 description 1
235000011285 magnesium acetate Nutrition 0.000 description 1
229940069446 magnesium acetate Drugs 0.000 description 1
239000000463 material Substances 0.000 description 1
230000013011 mating Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000008018 melting Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000002025 microglial effect Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
229940097886 phosphorus 32 Drugs 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
238000007747 plating Methods 0.000 description 1
230000004983 pleiotropic effect Effects 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000037452 priming Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000003757 reverse transcription PCR Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
229940016590 sarkosyl Drugs 0.000 description 1
108700004121 sarkosyl Proteins 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
235000008979 vitamin B4 Nutrition 0.000 description 1
238000005406 washing Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Toxicology (AREA)
Cell Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Investigating Or Analysing Biological Materials (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO19982550A 1995-12-06 1998-06-04 Renset peptid, isolert nukleinsyresekvens og deres anvendelse. NO324775B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9514424A FR2742156A1 (fr)	1995-12-06	1995-12-06	Polypeptide recepteur de l'il-13
PCT/FR1996/001756 WO1997020926A1 (fr)	1995-12-06	1996-11-07	Polypeptide recepteur de l'il-i3

Publications (3)

Publication Number	Publication Date
NO982550D0 NO982550D0 (no)	1998-06-04
NO982550L NO982550L (no)	1998-08-05
NO324775B1 true NO324775B1 (no)	2007-12-10

Family

ID=9485198

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
NO19982550A NO324775B1 (no)	1995-12-06	1998-06-04	Renset peptid, isolert nukleinsyresekvens og deres anvendelse.
NO20074034A NO328197B1 (no)	1995-12-06	2007-08-03	Anvendelse av en probe, anvendelse av en sekvens og fremgangsmate for in vitro diagnose.
NO20092994A NO331148B1 (no)	1995-12-06	2009-09-11	Anvendelse av et monoklonalt eller polyklonalt antistoff, samt fremgangsmate og kit for in vitro diagnose.

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
NO20074034A NO328197B1 (no)	1995-12-06	2007-08-03	Anvendelse av en probe, anvendelse av en sekvens og fremgangsmate for in vitro diagnose.
NO20092994A NO331148B1 (no)	1995-12-06	2009-09-11	Anvendelse av et monoklonalt eller polyklonalt antistoff, samt fremgangsmate og kit for in vitro diagnose.

Country Status (19)

Country	Link
US (4)	US7928073B2 (de)
EP (1)	EP0876482B1 (de)
JP (3)	JP3415162B2 (de)
AR (2)	AR004860A1 (de)
AT (1)	ATE234922T1 (de)
AU (1)	AU7576096A (de)
BR (1)	BR9611697B1 (de)
CA (1)	CA2238893C (de)
DE (1)	DE69626859T2 (de)
DK (1)	DK0876482T3 (de)
ES (1)	ES2192620T3 (de)
FR (1)	FR2742156A1 (de)
MX (1)	MX9804419A (de)
MY (1)	MY123740A (de)
NO (3)	NO324775B1 (de)
PT (1)	PT876482E (de)
TW (1)	TW565570B (de)
WO (1)	WO1997020926A1 (de)
ZA (1)	ZA9610238B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6911530B1 (en)	1995-10-23	2005-06-28	Amrad Operations, Pty., Ltd.	Haemopoietin receptor and genetic sequences encoding same
JP4224135B2 (ja) *	1995-10-23	2009-02-12	ズィナイスセラピューティックスピーティーワイ．エルティーディー．	新規なヘモポエチン受容体およびそれをコードする遺伝子配列
US5710023A (en)	1996-03-01	1998-01-20	Genetics Institute, Inc.	IL-13 cytokine receptor chain
US7078494B1 (en)	1996-03-01	2006-07-18	Genetics Institute, Llc	Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding
EP0812913A3 (de) *	1996-06-12	1999-08-04	Smithkline Beecham Corporation	HR1 Rezeptor, ein Rezeptor der Zytokinrezeptor-Familie
WO1998010638A1 (en) *	1996-09-10	1998-03-19	Amrad Operations Pty. Ltd.	Therapeutic molecules
US6743604B1 (en)	1996-12-13	2004-06-01	Smithkline Beecham Corporation	Substances and their uses
GB9625899D0 (en) *	1996-12-13	1997-01-29	Glaxo Group Ltd	Substances and their uses
US7198789B2 (en)	1998-03-17	2007-04-03	Genetics Institute, Llc	Methods and compositions for modulating interleukin-21 receptor activity
US7189400B2 (en)	1998-03-17	2007-03-13	Genetics Institute, Llc	Methods of treatment with antagonists of MU-1
US6057128A (en)	1998-03-17	2000-05-02	Genetics Institute, Inc.	MU-1, member of the cytokine receptor family
CA2235420A1 (en) *	1998-06-17	1999-12-17	Paolo Renzi	Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
US7553487B2 (en)	1998-12-14	2009-06-30	Genetics Institute, Llc	Method and compositions for treating asthma
MXPA01006006A (es)	1998-12-14	2004-08-12	Genetics Inst	Cadena receptora de citocina.
WO2001058479A1 (en) *	2000-02-08	2001-08-16	The Penn State Research Foundation	Immunotherapy using interleukin 13 receptor subunit alpha 2
US6703360B2 (en)	2000-04-07	2004-03-09	Heska Corporation	Compositions and methods related to canine IgG and canine IL-13 receptors
US7314623B2 (en)	2002-07-15	2008-01-01	Wyeth	Methods and compositions for modulating T helper (Th) cell development and function
PL3718564T3 (pl)	2003-12-23	2024-03-18	Genentech, Inc.	Nowe przeciwciała anty-IL 13 i ich zastosowania
US20090098142A1 (en) *	2004-06-09	2009-04-16	Kasaian Marion T	Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
AR049390A1 (es)	2004-06-09	2006-07-26	Wyeth Corp	Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en)	2004-06-17	2009-03-10	Wyeth	IL-13 binding agents
WO2006045202A1 (en)	2004-10-29	2006-05-04	Topigen Pharmaceuticals Inc.	Antisense oligonucleotides for treating allergy and neoplastic cell proliferation
EP1824886B1 (de)	2004-11-17	2010-12-22	Amgen Inc.	Vollständige humane monoklonale antikörper gegen il-13
GB0615881D0 (en) *	2006-08-10	2006-09-20	Univ Southampton	Novel peptide for treatment of asthma
AR066240A1 (es) *	2007-04-23	2009-08-05	Wyeth Corp	Metodos y composiciones para tratar y monitorear el tratamiento de trastornos asociados con il-13
EP2850093B1 (de)	2012-01-27	2019-01-09	The Board of Trustees of the Leland Stanford Junior University	Therapeutische il-13-polypeptide
CN104619334A (zh)	2012-08-09	2015-05-13	利兰斯坦福初级大学董事会	超级因子和合成因子:具有新的和增强的信号传导活性的经改造细胞因子
EP2970492B1 (de)	2013-03-15	2019-05-08	Wake Forest University Health Sciences	Antikörper gegen menschliches und hunde-il-13ra2
RU2016107435A (ru)	2013-09-13	2017-10-18	Дженентек, Инк.	Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
CN120904322A (zh)	2013-09-13	2025-11-07	豪夫迈·罗氏有限公司	包含纯化的重组多肽的方法和组合物
EP3049526B1 (de)	2013-09-24	2021-02-24	Medicenna Therapeutics, Inc.	Interleukin-4 rezeptor-bindende fusionsproteine und verwendungen davon
EP3694558B1 (de)	2017-10-10	2024-04-10	Medicenna Therapeutics Inc.	Il-4-fusionsformulierungen zur behandlung von tumoren des zentralen nervensystems (zns)
WO2019239213A2 (en)	2018-06-01	2019-12-19	Medicenna Therapeutics Inc.	Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
US12590133B2 (en)	2018-06-01	2026-03-31	The Board Of Trustees Of The Leland Stanford Junior University	IL-13/IL-4 superkines: immune cell targeting constructs and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4554101A (en) *	1981-01-09	1985-11-19	New York Blood Center, Inc.	Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4946778A (en) *	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5565332A (en) *	1991-09-23	1996-10-15	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
US5596072A (en)	1992-08-21	1997-01-21	Schering Corporation	Method of refolding human IL-13
US5587459A (en) *	1994-08-19	1996-12-24	Regents Of The University Of Minnesota	Immunoconjugates comprising tyrosine kinase inhibitors
US6911530B1 (en) *	1995-10-23	2005-06-28	Amrad Operations, Pty., Ltd.	Haemopoietin receptor and genetic sequences encoding same
US5710023A (en) *	1996-03-01	1998-01-20	Genetics Institute, Inc.	IL-13 cytokine receptor chain

1995
- 1995-12-06 FR FR9514424A patent/FR2742156A1/fr active Pending
1996
- 1996-11-07 CA CA2238893A patent/CA2238893C/fr not_active Expired - Fee Related
- 1996-11-07 PT PT96938273T patent/PT876482E/pt unknown
- 1996-11-07 JP JP52101797A patent/JP3415162B2/ja not_active Expired - Fee Related
- 1996-11-07 EP EP96938273A patent/EP0876482B1/de not_active Revoked
- 1996-11-07 ES ES96938273T patent/ES2192620T3/es not_active Expired - Lifetime
- 1996-11-07 DK DK96938273T patent/DK0876482T3/da active
- 1996-11-07 AT AT96938273T patent/ATE234922T1/de active
- 1996-11-07 BR BRPI9611697-8B1A patent/BR9611697B1/pt not_active IP Right Cessation
- 1996-11-07 AU AU75760/96A patent/AU7576096A/en not_active Abandoned
- 1996-11-07 DE DE69626859T patent/DE69626859T2/de not_active Expired - Lifetime
- 1996-11-07 WO PCT/FR1996/001756 patent/WO1997020926A1/fr not_active Ceased
- 1996-12-02 MY MYPI96005058A patent/MY123740A/en unknown
- 1996-12-05 TW TW085115042A patent/TW565570B/zh not_active IP Right Cessation
- 1996-12-05 ZA ZA9610238A patent/ZA9610238B/xx unknown
- 1996-12-05 AR ARP960105500A patent/AR004860A1/es active IP Right Grant
1998
- 1998-06-03 MX MX9804419A patent/MX9804419A/es active IP Right Grant
- 1998-06-04 NO NO19982550A patent/NO324775B1/no not_active IP Right Cessation
2002
- 2002-09-18 JP JP2002271902A patent/JP3737793B2/ja not_active Expired - Fee Related
2005
- 2005-05-06 JP JP2005135217A patent/JP4185070B2/ja not_active Expired - Fee Related
- 2005-07-15 US US11/182,384 patent/US7928073B2/en not_active Expired - Fee Related
- 2005-07-15 US US11/183,599 patent/US20060035856A1/en not_active Abandoned
- 2005-07-18 US US11/185,230 patent/US20050282216A1/en not_active Abandoned
2006
- 2006-10-25 AR ARP060104650A patent/AR056723A2/es active IP Right Grant
2007
- 2007-08-03 NO NO20074034A patent/NO328197B1/no not_active IP Right Cessation
2009
- 2009-09-11 NO NO20092994A patent/NO331148B1/no not_active IP Right Cessation
2011
- 2011-02-15 US US13/027,425 patent/US8318910B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AR004860A1 (es)	1999-03-10
JPH11511028A (ja)	1999-09-28
CA2238893A1 (fr)	1997-06-12
BR9611697B1 (pt)	2013-09-17
ZA9610238B (en)	1998-06-05
CA2238893C (fr)	2013-10-08
ES2192620T3 (es)	2003-10-16
US20050282216A1 (en)	2005-12-22
MY123740A (en)	2006-06-30
NO982550D0 (no)	1998-06-04
DE69626859D1 (de)	2003-04-24
US20110201029A1 (en)	2011-08-18
NO328197B1 (no)	2010-01-04
AR056723A2 (es)	2007-10-17
NO20074034L (no)	1998-08-05
ATE234922T1 (de)	2003-04-15
MX9804419A (es)	1998-09-30
US8318910B2 (en)	2012-11-27
JP3415162B2 (ja)	2003-06-09
JP4185070B2 (ja)	2008-11-19
JP2005323595A (ja)	2005-11-24
EP0876482A1 (de)	1998-11-11
NO982550L (no)	1998-08-05
NO20092994L (no)	1998-08-05
NO331148B1 (no)	2011-10-24
DK0876482T3 (da)	2003-07-21
BR9611697A (pt)	1999-02-17
DE69626859T2 (de)	2003-12-24
EP0876482B1 (de)	2003-03-19
TW565570B (en)	2003-12-11
FR2742156A1 (fr)	1997-06-13
WO1997020926A1 (fr)	1997-06-12
AU7576096A (en)	1997-06-27
US7928073B2 (en)	2011-04-19
US20060035855A1 (en)	2006-02-16
US20060035856A1 (en)	2006-02-16
JP3737793B2 (ja)	2006-01-25
PT876482E (pt)	2003-07-31
JP2003180382A (ja)	2003-07-02

Legal Events

Date	Code	Title	Description
2016-06-27	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO324775B1 (no)	2007-12-10	Renset peptid, isolert nukleinsyresekvens og deres anvendelse.
Marchese et al.	1994	Cloning of human genes encoding novel G protein-coupled receptors
Takeshita et al.	1992	Cloning of the γ chain of the human IL-2 receptor
Sreedharan et al.	1991	Cloning and expression of the human vasoactive intestinal peptide receptor.
AU651596B2 (en)	1994-07-28	Type II interleukin-1 receptors
JP5015404B2 (ja)	2012-08-29	可溶性ｚｃｙｔｏｒ１１サイトカイン受容体
JP2000512492A (ja)	2000-09-26	造血サイトカイン受容体
NO306624B1 (no)	1999-11-29	Rekombinant DNA-molekyl som koder for <beta>-kjeden til en IL-2 reseptor
JP2001508309A (ja)	2001-06-26	ヘマトポイエチン受容体スーパーファミリーのメンバー
US6743604B1 (en)	2004-06-01	Substances and their uses
CN101627053A (zh)	2010-01-13	泛细胞表面受体特异的治疗剂
AU753400C (en)	2003-04-17	Orphan receptors
AU764484B2 (en)	2003-08-21	Orphan cytokine receptor
US20050118675A1 (en)	2005-06-02	Heptahelix receptor and its use as leukotriene B4 receptor
JPWO2000049148A1 (ja)	2002-06-04	新規サイトカイン受容体様タンパク質
JPH10313870A (ja)	1998-12-02	新規なｂ細胞表面タンパク質及びこれをコードするｄｎａ
JPWO2000049149A1 (ja)	2002-06-04	新規ｔｎｆ受容体様タンパク質